Kinetic profiling of novel spirobenzo-oxazinepiperidinone derivatives as equilibrative nucleoside transporter 1 inhibitors.
(Human) nucleoside transport protein (hENT1
Adenosine
Radioligand binding experiments
SLC29A1)
Target binding kinetics
Transport inhibitors
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
10 Jul 2023
10 Jul 2023
Historique:
received:
31
01
2023
accepted:
26
05
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
9
7
2023
Statut:
aheadofprint
Résumé
Evaluation of kinetic parameters of drug-target binding, k
Identifiants
pubmed: 37423967
doi: 10.1007/s11302-023-09948-9
pii: 10.1007/s11302-023-09948-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Young JD, Yao SY, Baldwin JM, Cass CE, Baldwin SA (2013) The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med 34(2–3):529–547
pubmed: 23506887
doi: 10.1016/j.mam.2012.05.007
Rehan S, Ashok Y, Nanekar R, Jaakola VP (2015) Thermodynamics and kinetics of inhibitor binding to human equilibrative nucleoside transporter subtype-1. Biochem Pharmacol 98(4):681–689
pubmed: 26428002
doi: 10.1016/j.bcp.2015.09.019
Blackburn GM, Gait MJ, Loakes D, Williams DM (2006) Nucleosides and Nucleotides. Nucleic acids in chemistry and biology: edition 3: Royal Soc Chem 125–35
Quashie NB, Ranford-Cartwright LC, de Koning HP (2010) Uptake of purines in Plasmodium falciparum-infected human erythrocytes is mostly mediated by the human equilibrative nucleoside transporter and the human facilitative nucleobase transporter. Malar J 9:36
pubmed: 20113503
pmcid: 2825241
doi: 10.1186/1475-2875-9-36
Molina-Arcas M, Casado FJ, Pastor-Anglada M (2009) Nucleoside transporter proteins. Curr Vasc Pharmacol 7(4):426–434
pubmed: 19485885
doi: 10.2174/157016109789043892
Mangravite LM, Xiao G, Giacomini KM (2003) Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells. Am J Physiol Renal Physiol 284(5):F902–F910
pubmed: 12527552
doi: 10.1152/ajprenal.00215.2002
Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD (2004) The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447(5):735–743
pubmed: 12838422
doi: 10.1007/s00424-003-1103-2
Pastor-Anglada M, Perez-Torras S (2018) Emerging roles of nucleoside transporters. Front Pharmacol 9:606
pubmed: 29928232
pmcid: 5997781
doi: 10.3389/fphar.2018.00606
Mikdar M, González-Menéndez P, Cai X, Zhang Y, Serra M, Dembele AK et al (2021) The equilibrative nucleoside transporter ENT1 is critical for nucleotide homeostasis and optimal erythropoiesis. Blood 137(25):3548–3562
pubmed: 33690842
pmcid: 8225918
doi: 10.1182/blood.2020007281
Niemann B, Haufs-Brusberg S, Puetz L, Feickert M, Jaeckstein MY, Hoffmann A et al (2022) Apoptotic brown adipocytes enhance energy expenditure via extracellular inosine. Nature 609(7926):361–368
pubmed: 35790189
pmcid: 9452294
doi: 10.1038/s41586-022-05041-0
Yan L, Tang Y (2023) Increasing inosine/decreasing ENT1: promising strategies for anti-obesity therapy. Purinergic Signalling 19:383–385. https://doi.org/10.1007/s11302-023-09920-7
Lane J, Martin TA, McGuigan C, Mason MD, Jiang WG (2010) The differential expression of hCNT1 and hENT1 in breast cancer and the possible impact on breast cancer therapy. J Exp Ther Oncol 8(3):203–210
pubmed: 20734919
Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF et al (2014) Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Nat Cancer Inst 106(1):djt347
pubmed: 24301456
doi: 10.1093/jnci/djt347
Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR (2001) Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280(3):951–959
pubmed: 11162617
doi: 10.1006/bbrc.2000.4205
Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB et al (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22(47):7524–7536
pubmed: 14576856
doi: 10.1038/sj.onc.1206952
Andersen K, Dellborg M, Swedberg K (1996) Nucleoside transport inhibition by draflazine in unstable coronary disease. Eur J Clin Pharmacol 51(1):7–13
pubmed: 8880045
doi: 10.1007/s002280050153
Deguchi H, Takeya H, Wada H, Gabazza EC, Hayashi N, Urano H et al (1997) Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood 90(6):2345–2356
pubmed: 9310485
doi: 10.1182/blood.V90.6.2345
Khalil A, Belal F, Al-Badr AA (2005) Dipyridamole: comprehensive profile. Profiles Drug Subst Excipients Relat Methodol 31:215–280
doi: 10.1016/S0099-5428(04)31007-5
Swinney DC (2009) The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 12(1):31–39
pubmed: 19152211
Guo D, Hillger JM, IJzerman AP, Heitman LH (2014) Drug-target residence time–a case for G protein-coupled receptors. Med Res Rev 34(4):856–92
pubmed: 24549504
doi: 10.1002/med.21307
Copeland RA (2016) The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov 15(2):87–95
pubmed: 26678621
doi: 10.1038/nrd.2015.18
Vlachodimou A, Konstantinopoulou K, IJzerman AP, Heitman LH (2020) Affinity, binding kinetics and functional characterization of draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1). Biochem Pharmacol 172:113747
pubmed: 31830468
doi: 10.1016/j.bcp.2019.113747
Bosmans JP, Berthelot D, Pieters S, Verbist B, De Cleyn M, inventors; Janssen Pharmaceutica NV, assignee (2007) Equilibrative nucleoside transport ENT1 inhibitors. Belgium patent EP2209790
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150(1):76–85
pubmed: 3843705
doi: 10.1016/0003-2697(85)90442-7
Motulsky HJ, Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25(1):1–9
pubmed: 6708928
Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal 46:1–265
pubmed: 16350889
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23):3099–3108
pubmed: 4202581
doi: 10.1016/0006-2952(73)90196-2
Liu W, Jiang J, Lin Y, You Q, Wang L (2022) Insight into thermodynamic and kinetic profiles in small-molecule optimization. J Med Chem 65(16):10809–10847
pubmed: 35969687
doi: 10.1021/acs.jmedchem.2c00682
van der Velden WJC, Heitman LH, Rosenkilde MM (2020) Perspective: implications of ligand-receptor binding kinetics for therapeutic targeting of G protein-coupled receptors. ACS Pharmacol Transl Sci 3(2):179–189
pubmed: 32296761
pmcid: 7155193
doi: 10.1021/acsptsci.0c00012
Xia L, Burger WAC, van Veldhoven JPD, Kuiper BJ, van Duijl TT, Lenselink EB et al (2017) Structure–affinity relationships and structure–kinetics relationships of pyrido[2,1-f]purine-2,4-dione derivatives as human adenosine A3 receptor antagonists. J Med Chem 60(17):7555–7568
pubmed: 28806076
pmcid: 5601358
doi: 10.1021/acs.jmedchem.7b00950
de Witte WEA, Danhof M, van der Graaf PH, de Lange ECM (2016) In vivo target residence time and kinetic selectivity: the association rate constant as determinant. Trends Pharmacol Sci 37(10):831–842
pubmed: 27394919
doi: 10.1016/j.tips.2016.06.008
Vauquelin G, Charlton SJ (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161(3):488–508
pubmed: 20880390
pmcid: 2990149
doi: 10.1111/j.1476-5381.2010.00936.x
IJzerman AP, Guo D (2019) Drug-target association kinetics in drug discovery. Trends Biochem Sci 44(10):861–71
pubmed: 31101454
doi: 10.1016/j.tibs.2019.04.004
Schoop A, Dey F (2015) On-rate based optimization of structure-kinetic relationship–surfing the kinetic map. Drug Discov Today Technol 17:9–15
pubmed: 26724331
doi: 10.1016/j.ddtec.2015.08.003
Vauquelin G (2016) Effects of target binding kinetics on in vivo drug efficacy: koff, kon and rebinding. Br J Pharmacol 173(15):2319–2334
pubmed: 27129075
pmcid: 4945762
doi: 10.1111/bph.13504
Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53(4):527–52
pubmed: 11734617
Baloch K, Chen L, Memon AA, Dexter L, Irving W, Ilyas M et al (2017) Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Antivir Chem Chemother 25(1):2–10
pubmed: 28417642
pmcid: 5890492
doi: 10.1177/2040206616686894
Thiagarajan P, Parker CJ, Prchal JT (2021) How do red blood cells die? Front Physiol 12:655393
pubmed: 33790808
pmcid: 8006275
doi: 10.3389/fphys.2021.655393
Rongen GA, Smits P, Ver Donck K, Willemsen JJ, De Abreu RA, Van Belle H et al (1995) Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. J Clin Invest 95(2):658–68
pubmed: 7860749
pmcid: 295532
doi: 10.1172/JCI117711
Rosenbrier Ribeiro L, Ian SR (2017) A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm. Toxicol Appl Pharmacol 317:41–50
pubmed: 28041785
doi: 10.1016/j.taap.2016.12.021
Tummino PJ, Copeland RA (2008) Residence time of receptor−ligand complexes and its effect on biological function. Biochemistry 47(20):5481–5492
pubmed: 18412369
doi: 10.1021/bi8002023
Chang CP, Chang YG, Chuang PY, Nguyen TNA, Wu KC, Chou FY et al (2021) Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. Acta Neuropathol Commun 9(1):112
pubmed: 34158119
pmcid: 8220833
doi: 10.1186/s40478-021-01213-7
Tonge PJ (2018) Drug-target kinetics in drug discovery. ACS Chem Neurosci 9(1):29–39
pubmed: 28640596
doi: 10.1021/acschemneuro.7b00185
Doornbos MLJ, Cid JM, Haubrich J, Nunes A, van de Sande JW, Vermond SC et al (2017) Discovery and kinetic profiling of 7-Aryl-1,2,4-triazolo[4,3-a]pyridines: positive allosteric modulators of the metabotropic glutamate receptor 2. J Med Chem 60(15):6704–6720
pubmed: 28704052
doi: 10.1021/acs.jmedchem.7b00669
de Witte WEA, Vauquelin G, van der Graaf PH, de Lange ECM (2017) The influence of drug distribution and drug-target binding on target occupancy: the rate-limiting step approximation. Euro J Pharm Sci : official journal of the European Federation for Pharmaceutical Sciences 109s:S83-s9
doi: 10.1016/j.ejps.2017.05.024
Wright NJ, Lee S-Y (2019) Structures of human ENT1 in complex with adenosine reuptake inhibitors. Nat Struct Mol Biol 26(7):599–606
pubmed: 31235912
pmcid: 6705415
doi: 10.1038/s41594-019-0245-7